-
Mashup Score: 5
PURPOSE Despite fibroblast growth factor receptor (FGFR) inhibitors being approved in tumor types with select FGFR rearrangements or gene mutations, amplifications of FGFR represent the most common FGFR alteration across malignancies. Subprotocol K1 (EAY131-K1) of the National Cancer Institute-MATCH platform trial was designed to evaluate the antitumor efficacy of the oral FGFR1-4 inhibitor, erdafitinib, in patients with tumors harboring FGFR1-4 amplification. METHODS EAY131-K1 was an open-label, single-arm, phase II study with central confirmation of presence of FGFR1-4 amplification in tumors. Patients with urothelial carcinoma were excluded. Enrolled patients received oral erdafitinib at a starting dose of 8 mg once daily continuously with escalation to 9 mg once daily continuously, on the basis of predefined time point assessments of phosphate levels, until disease progression or intolerable toxicity. The primary end point was centrally assessed objective response rate (ORR), with
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21FTC, 10 States Take Action Against Operator of Sham Cancer Charity for Deceiving Donors - 2 month(s) ago
The Federal Trade Commission and 10 states are suing sham charity Cancer Recovery Foundation International, also known as Women’s Cancer Fund, and its operator, Gregory B.
Source: www.ftc.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases - 2 month(s) ago
Objective To assess the risks of breast cancer associated with different types and durations of hormone replacement therapy (HRT). Design Two nested case-control studies. Setting UK general practices contributing to QResearch or Clinical Practice Research Datalink (CPRD), linked to hospital, mortality, social deprivation, and cancer registry (QResearch only) data. Participants 98 611 women aged 50-79 with a primary diagnosis of breast cancer between 1998 and 2018, matched by age, general practice, and index date to 457 498 female controls. Main outcome measures Breast cancer diagnosis from general practice, mortality, hospital, or cancer registry records. Odds ratios for HRT types, adjusted for personal characteristics, smoking status, alcohol consumption, comorbidities, family history, and other prescribed drugs. Separate results from QResearch or CPRD were combined. Results Overall, 33 703 (34%) women with a diagnosis of breast cancer and 134 391 (31%) controls had used HRT prior to
Source: www.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence - 2 month(s) ago
If these associations are largely causal, then for women of average weight in developed countries, 5 years of MHT, starting at age 50 years, would increase breast cancer incidence at ages 50–69 years by about one in every 50 users of oestrogen plus daily progestagen preparations; one in every 70 users of oestrogen plus intermittent progestagen preparations; and one in every 200 users of oestrogen-only preparations. The corresponding excesses from 10 years of MHT would be about twice as great.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 60A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer - PubMed - 2 month(s) ago
NCT02776917. Registered on ClinicalTrials.gov on 05/17/2016.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23The Candida Diet: Beginner's Guide and Meal Plan - 2 month(s) ago
Candida overgrowth can cause unpleasant symptoms like digestive issues, fatigue or mood disorders, but dietary changes may help. Here’s a beginner’s guide to the candida diet and a sample meal plan.
Source: www.healthline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3stats - 2 month(s) ago
Invasive candidiasis definition, symptoms, risk and prevention, sources of infection, diagnosis, treatment, information for healthcare professionals, statistics, and more resources.
Source: www.cdc.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Annual Oncology Summit & Research Symposium - 2 month(s) ago
Renowned experts in the field of oncology will deliver keynote addresses, sharing their knowledge and expertise on the latest advancements, novel therapeutic approaches, and clinical breakthroughs. Attendees will have the opportunity to learn from leading
Source: moasc.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Opinion: Hospitals are struggling as health insurers, such as Anthem Blue Cross, maximize profits - 3 month(s) ago
Anthem Blue Cross’s decision to withdraw from an agreement with the University of California reflects its willingness to disrupt the provider-patient relationship to maximize profit
Source: www.sandiegouniontribune.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 14Health Plans Can’t Dodge Paying for Expensive New Cancer Treatments, Says Michigan’s Top Insurance Regulator - 4 month(s) ago
After ProPublica reported on a health insurer that refused to cover the only medicine that could save a cancer patient’s life, Michigan insurance regulators clarified that, by law, many plans must pay for any clinically proven treatments.
Source: www.propublica.orgCategories: General Medicine News, Hem/OncsTweet
Ugh, I was really hoping this would be positive. Anyone have ideas on 🎯FGFR amplification ?#onctwitter Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial| JCO Precision Oncology https://t.co/XSIhiXrhHT